KR20150035585A - 4-[5-(피리딘-4-일)-1h-1,2,4-트리아졸-3-일]피리딘-2-카르보니트릴의 결정 다형 및 그의 제조방법 - Google Patents

4-[5-(피리딘-4-일)-1h-1,2,4-트리아졸-3-일]피리딘-2-카르보니트릴의 결정 다형 및 그의 제조방법 Download PDF

Info

Publication number
KR20150035585A
KR20150035585A KR20147034603A KR20147034603A KR20150035585A KR 20150035585 A KR20150035585 A KR 20150035585A KR 20147034603 A KR20147034603 A KR 20147034603A KR 20147034603 A KR20147034603 A KR 20147034603A KR 20150035585 A KR20150035585 A KR 20150035585A
Authority
KR
South Korea
Prior art keywords
pyridine
pyridin
carbonitrile
triazol
crystal
Prior art date
Application number
KR20147034603A
Other languages
English (en)
Korean (ko)
Inventor
요시유키 이와부치
사치호 미야타
타카히로 사토
준이치로 우다
타카미츠 칸도우
타다시 이노우에
히로유키 나카노
Original Assignee
가부시키가이샤 후지야쿠힝
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49997324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150035585(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 가부시키가이샤 후지야쿠힝 filed Critical 가부시키가이샤 후지야쿠힝
Publication of KR20150035585A publication Critical patent/KR20150035585A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR20147034603A 2012-07-25 2013-07-24 4-[5-(피리딘-4-일)-1h-1,2,4-트리아졸-3-일]피리딘-2-카르보니트릴의 결정 다형 및 그의 제조방법 KR20150035585A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012177539 2012-07-25
JPJP-P-2012-177539 2012-07-25
PCT/JP2013/070004 WO2014017515A1 (ja) 2012-07-25 2013-07-24 ４－［５－（ピリジン－４－イル）－１ｈ－１，２，４－トリアゾール－３－イル］ピリジン－２－カルボニトリルの結晶多形およびその製造方法

Publications (1)

Publication Number Publication Date
KR20150035585A true KR20150035585A (ko) 2015-04-06

Family

ID=49997324

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147034603A KR20150035585A (ko) 2012-07-25 2013-07-24 4-[5-(피리딘-4-일)-1h-1,2,4-트리아졸-3-일]피리딘-2-카르보니트릴의 결정 다형 및 그의 제조방법

Country Status (18)

Country Link
US (1) US9199970B2 (ja)
EP (1) EP2878598B1 (ja)
JP (1) JP6158811B2 (ja)
KR (1) KR20150035585A (ja)
CN (1) CN104411700B (ja)
AU (1) AU2013293973B2 (ja)
CA (1) CA2876391C (ja)
DK (1) DK2878598T3 (ja)
ES (1) ES2732360T3 (ja)
HK (1) HK1205101A1 (ja)
HU (1) HUE045138T2 (ja)
IL (1) IL236130B (ja)
NZ (1) NZ703638A (ja)
RU (1) RU2639149C2 (ja)
TR (1) TR201909969T4 (ja)
TW (1) TWI598346B (ja)
WO (1) WO2014017515A1 (ja)
ZA (1) ZA201500468B (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315260A (zh) * 2014-07-29 2016-02-10 北京海步医药科技股份有限公司 一种托布司他一水合物晶型及其制备方法
WO2016134854A1 (en) 2015-02-25 2016-09-01 Pharmathen S.A. Methods for the preparation of topiroxostat and intermediates thereof
CN105693699B (zh) * 2015-03-30 2019-06-18 苏州晶云药物科技股份有限公司 托吡司他的晶型及其制备方法
CN106279111A (zh) * 2015-05-12 2017-01-04 北京济美堂医药研究有限公司 一种精制托吡司他的新方法
CN104961730B (zh) * 2015-06-18 2017-05-17 山东金城医药化工股份有限公司 托吡司他新晶型及其制备方法
CN105130958B (zh) * 2015-08-31 2017-10-31 济南康和医药科技有限公司 5‑(2‑氰基4‑吡啶基)‑3‑(4‑吡啶基)‑1,2,4‑三唑的制备工艺
CN107759570B (zh) * 2016-08-18 2019-09-03 山东诚创医药技术开发有限公司 一种托普司他对甲苯磺酸盐的精制方法
CN108250183A (zh) * 2016-12-29 2018-07-06 北京诚济制药有限公司 一种高纯度的托匹司他的制备方法
WO2018190820A1 (en) 2017-04-12 2018-10-18 Hewlett-Packard Development Company, L.P. Printing subassembly
CN107089971A (zh) * 2017-05-10 2017-08-25 山东新华制药股份有限公司 高纯度托匹司他的制备方法
CN107474040A (zh) * 2017-08-21 2017-12-15 赵剑锋 一种5‑（2‑氰基‑4‑吡啶基）‑3‑（4‑吡啶基）‑1,2,4‑三唑的精制方法
CN109620756B (zh) * 2018-12-10 2021-12-17 广州市晶硅新材料有限公司 一种化妆品用有机硅复合粉末及其制备方法
CN110613692A (zh) * 2019-09-17 2019-12-27 杭州百诚医药科技股份有限公司 一种托匹司他片剂及其制备方法
CN116421573B (zh) * 2023-05-06 2024-02-23 湖南一格制药有限公司 托吡司特缓释制剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089923A9 (en) 2000-01-07 2005-04-28 Levinson Douglas A. Method and system for planning, performing, and assessing high-throughput screening of multicomponent chemical compositions and solid forms of compounds
US6977723B2 (en) 2000-01-07 2005-12-20 Transform Pharmaceuticals, Inc. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
US20070020662A1 (en) 2000-01-07 2007-01-25 Transform Pharmaceuticals, Inc. Computerized control of high-throughput experimental processing and digital analysis of comparative samples for a compound of interest
US20070021929A1 (en) 2000-01-07 2007-01-25 Transform Pharmaceuticals, Inc. Computing methods for control of high-throughput experimental processing, digital analysis, and re-arraying comparative samples in computer-designed arrays
US7108970B2 (en) 2000-01-07 2006-09-19 Transform Pharmaceuticals, Inc. Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
US20050118637A9 (en) 2000-01-07 2005-06-02 Levinson Douglas A. Method and system for planning, performing, and assessing high-throughput screening of multicomponent chemical compositions and solid forms of compounds
US20050095696A9 (en) 2000-01-07 2005-05-05 Lemmo Anthony V. Apparatus and method for high-throughput preparation and characterization of compositions
AU2930501A (en) 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
AU2002336457A1 (en) 2001-09-07 2003-03-24 Transform Pharmaceuticals, Inc. Apparatus and method for high-throughput preparation and characterization of compositions
DK1471065T3 (da) * 2002-01-28 2008-03-25 Fuji Yakuhin Co Ltd Hidtil ukendt 1,2,4-triazolforbindelse
WO2005009991A1 (ja) * 2003-07-24 2005-02-03 Fujiyakuhin Co., Ltd. １，２，４−トリアゾール化合物の製造方法及びその中間体
JP2005041802A (ja) 2003-07-25 2005-02-17 Fujiyakuhin Co Ltd １，２，４−トリアゾール化合物の製造方法
US20060189811A1 (en) 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor

Also Published As

Publication number Publication date
CA2876391C (en) 2016-10-18
AU2013293973A1 (en) 2015-01-29
CA2876391A1 (en) 2014-01-30
IL236130A0 (en) 2015-02-01
IL236130B (en) 2019-08-29
ZA201500468B (en) 2016-10-26
JPWO2014017515A1 (ja) 2016-07-11
JP6158811B2 (ja) 2017-07-05
TR201909969T4 (tr) 2019-07-22
US20150126558A1 (en) 2015-05-07
RU2015106137A (ru) 2016-09-20
TW201408659A (zh) 2014-03-01
TWI598346B (zh) 2017-09-11
NZ703638A (en) 2017-02-24
EP2878598A1 (en) 2015-06-03
EP2878598A4 (en) 2016-04-06
US9199970B2 (en) 2015-12-01
ES2732360T3 (es) 2019-11-22
CN104411700A (zh) 2015-03-11
EP2878598B1 (en) 2019-06-19
HUE045138T2 (hu) 2019-12-30
WO2014017515A1 (ja) 2014-01-30
RU2639149C2 (ru) 2017-12-20
CN104411700B (zh) 2016-06-15
AU2013293973B2 (en) 2017-04-06
HK1205101A1 (en) 2015-12-11
DK2878598T3 (da) 2019-08-12

Similar Documents

Publication Publication Date Title
KR20150035585A (ko) 4-[5-(피리딘-4-일)-1h-1,2,4-트리아졸-3-일]피리딘-2-카르보니트릴의 결정 다형 및 그의 제조방법
JP6609065B2 (ja) １−（５−（２，４−ジフルオロフェニル）−１−（（３−フルオロフェニル）スルホニル）−４−メトキシ−１ｈ−ピロール−３−イル）−ｎ−メチルメタンアミンの新規な酸付加塩
JP7050093B2 (ja) 置換５員および６員複素環式化合物、その調製方法、薬剤の組み合わせおよびその使用
US9895377B2 (en) Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
EP1742933A2 (en) Crystalline methanesulfonic acid addition salts of imatinib
EP3433233B1 (en) Novel crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine salt
JPWO2020009156A1 (ja) ビアリールエーテル型キナゾリン誘導体
CZ201629A3 (cs) Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy
WO2011108953A1 (en) PROCESS FOR PREPARATION OF POLYMORPHIC FORM α AND NEW POLYMORPHIC FORM OF IMATINIB MESYLATE ISOLATED IN THAT PROCESS
WO2015085972A1 (en) NOVEL SALTS OF 3-(2-IMIDAZO[1,2-b]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-[4-[(4-METHYL- 1-PIPERAZINYL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL] BENZAMIDE
KR20220016949A (ko) Cdk9 억제제의 결정다형 및 이의 제조방법과 용도
CA3222612A1 (en) New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
WO2015085971A1 (en) Hydrobromide salt of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide
EP3941472A1 (en) <smallcaps/>? ? ?n? ? ? ? ?crystalline and amorphous forms of-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2 <ns1:i>h</ns1:i>?-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
BR112020006051A2 (pt) formas cristalinas de lenalidomida
CN110903291B (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法
CN109796400B (zh) 一种甲苯磺酸索拉菲尼晶型及其制备方法
TWI809330B (zh) Cdk9抑制劑的多晶型物及其製法和用途
WO2023093861A1 (zh) Axl激酶抑制剂的单对甲苯磺酸盐及其晶型
TWI707851B (zh) 哌嗪化合物的新穎結晶
JP2022527910A (ja) Ａ２ａ受容体アンタゴニストの塩形態、結晶形態及びその製造方法
CN116813624A (zh) 一种jak2抑制剂的晶型及制备方法
CN114014804A (zh) 含氟的氘代ω-二苯基脲水合物及其晶型物
SK288226B6 (sk) Kryštalická alfa-forma Imatinib mezylátu s novým habitom a spôsob jeho prípravy a použitie

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application